Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity
Open Access
- 22 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 61 (3) , 426-430
Abstract
We retrospectively reviewed the effect of stereotactic body radiation therapy (SBRT) in patients with stage I lung cancer whose lung tumor showed a nodular appearance of ground glass opacity, so-called ground glass nodule (GGN). A total of 84 patients (42 men, 42 women; mean age, 75 years) with stage I lung cancer with GGN accompanying a solid component 18F-FDG positron emission tomography (PET) examination. The median tumor size was 20 mm (range, 10–41 mm). All of the patients were treated with SBRT, and the total prescribed dose at the isocenter ranged between 48 Gy in four fractions and 84 Gy in ten fractions. Median follow-up duration was 33 months. No patient had local failure nor regional lymph node failure. The 3-year rate of distant failure was 2.6%. Two patients who experienced distant metastases had a past surgical history of initial lung cancer before SBRT. The rates of cause-specific and overall survival at 3 years were 98.2 and 94.6%, respectively. Treatment-related adverse events of ≥grade 4 were not reported. Although more cases and longer follow-ups are mandatory, SBRT may be one of the radical treatment options for patients with GGN.Keywords
Funding Information
- Japan Radiological Society (HK-22-3)
- Japan Society for the Promotion of Science (JP16H05389)
This publication has 17 references indexed in Scilit:
- Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancerLung Cancer, 2016
- Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsThe Lancet Oncology, 2015
- Sublobar resection for early-stage lung cancer2014
- The association between baseline clinical–radiological characteristics and growth of pulmonary nodules with ground-glass opacityLung Cancer, 2014
- A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)Journal of Thoracic Oncology, 2011
- Pulmonary Ground-Glass Opacity (GGO) Lesions–Large Size and a History of Lung Cancer are Risk Factors for GrowthJournal of Thoracic Oncology, 2008
- Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional StudyJournal of Thoracic Oncology, 2007
- Peripheral Lung Adenocarcinoma: Correlation of Thin-Section CT Findings with Histologic Prognostic Factors and SurvivalRadiology, 2001
- Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patientsActa Oncologica, 1995